Boehringer Ingelheim GMBH considers research pacts with academia a key part of its strategy, and while it leans more toward research collaborations than license- or option-based deals, the company tries to be agnostic about which type of deal structure will fit a specific agreement with academic researchers.
Paola Casarosa, BI's corporate VP for business development and licensing/prescription medicines, told Scrip her team uses a case-by-case approach to determine how to maximize a partnership with an academic institution....